The Global Registry Of COVID-19 Clinical Trials: Indicating The Design Of Traditional Chinese Medicine Clinical Trials

Mar 15, 2022


Contact: Audrey Hu Whatsapp/hp: 0086 13880143964 Email: audrey.hu@wecistanche.com


Abstract

Objective: To analyze the registration information of Corona Virus Disease 2019 (COVID-19) related clinical trials from all the clinical trial registries accepted by the International Committee of Medical Journal Editors (ICMJE). Methods: All the databases of the ICMJE-accepted clinical trial registry platform were searched for COVID-19 related clinical trials that registered from December 8, 2019, to February 19, 2020. Results: All the databases totally contained data of 209 COVID-19 related clinical trials, including 66(31.6%) traditional Chinese medicine (TCM) related studies and 143(68.4%) non-TCM related studies. 176(84.2%) clinical trials were registered in ChiCTR, as 33(15.8%) were registered in ClinicalTrials.gov. There were 152(72.7%) intervention trials, including 9(4.3% in total) preventive trials, 136(65.1% in total) therapeutic trials, and 7(3.3% in total) convalescent trials. Conclusion: At the present stage, clinical studies are still aiming at exploring the effective treatment of COVID-19, and the existing treatments need more high-quality clinical evidence supporting. Traditional Chinese medicine may have played an important role in all stages of epidemic prevention and control, and the enthusiasm for carrying out scientific research has also been greatly improved. The relevant policies of clinical trial registration should be popularized among researchers, including traditional Chinese medicine researchers. And the methodological quality of clinical trials’ design urges improving.

Keywords: COVID-19, Clinical trial, Register, Data analysis

CISTANCHE

EFFECTS OF CISTANCHE: ANTI-BACTERIAL

Background

Since the first case of Corona Virus Disease 2019 (COVID-19), which was caused by Severe Acute Respiratory Syndrome - Corona Virus - 2 (SARS-CoV-2), was discovered on December 8, 2019, the epidemic has widely spread. On January 20, 2020, COVID-19 was officially classified as class-B infectious diseases by the National Health Commission, and preventive measures for class A infectious diseases were taken [1]. On January 31, 2020, the epidemic of COVID-19 was announced as a Public Health Emergencies of International Concern (PHEIC) in Geneva.

As the epidemic spreads, the prevention and control measures are strengthening. At the same time, a large number of related medical scientific research projects are carrying out in China. Clinical trial plays an important role in COVID-19 related scientific research projects, as it is the necessary link to verify the clinical efficacy of treatments and produce clinical evidence. In view of this, COVID-19 related clinical trial registration information is investigated. The status and problems of COVID-19 related clinical trials’ registration are discussed in this article through reading them and analyzing their data.

Methods: Search strategy All the databases of the ICMJE-accepted clinical trial registry platform [2] were searched (Table 1) for COVID-19 related clinical trials that registered from December 8, 2019, to February 19, 2020, as the first case was discovered on December 8, 2019. The recruitment status, interventions, and study type were not restricted in order to maximize the number of potentially relevant studies identified.


The global registry of COVID-19 related clinical trials searching results and selection

“COVID-19”, “2019- novel Corona Virus (2019-nCoV)”, “Novel Coronavirus Pneumonia (NCP)”, “Severe Acute Respiratory Infection (SARI)”, “Severe Acute Respiratory Syndrome - Corona Virus- 2 (SARS-CoV-2)” was searched in Chinese Clinical Trial Registry (ChiCTR) through the entrance of “disease name” and “title”. Besides, the registration data officially published by ChiCTR are counted up to February 19, 2020, 11:54. “nCoV”, “Coronavirus”, “SARS”, “SARI”, “NCP”nCoV”, “Coronavirus”, “SARS”, “SARI”, “NCP” COVID” was searched in the Netherlands National Trial Register (NTR). Other clinical trial registry database was searched using “2019-nCoV OR Novel Coronavirus OR New Coronavirus OR SARS-CoV-2 OR SARI OR NCP OR Novel Coronavirus Pneumonia OR COVID-19 OR Wuhan pneumonia”.

Study selection After removing study duplicates, one of the authors reviewed all the records based on their titles in order to identify relevant studies. The patients, study type, interventions were not limited. Irrelevant studies were excluded. Data extraction An electronic data extraction form was adapted from ChiCTR registration items, developed in Microsoft Excel 2007. The compiled form includes general information about the registration, such as the publication date, contacts, principal investigator, sponsor, collaborators, objective, study type, inclusion criteria, exclusion criteria, sample size. Information of interventions, primary outcome, and the secondary outcome was also detailed in the data extraction form. Collaborators of studies registered in ChiCTR are counted through the item of “research sites”. And the patients were divided into “confirmed”, “suspected” and “high risk” according to the eligibility criteria. Two authors (Xuxu Wei, Mengzhu Zhao) independently extracted data from the articles. All extracted data were presented, compared, and discussed.

CISTANCHE

EFFECTS OF CISTANCHE: IMPROVE IMMUNITY

Results

Increasing registration There are 209 included registered clinical trials, consisting of 66 (31.6%) traditional Chinese medicine (TCM) related studies and 143 (68.4%) non-TCM related studies. Figure 1 shows how the cumulative quantity of registration grew. The quantity continuously increased since January 31.


Trend chart of cumulative registration of COVID-19 related clinical trials

Registry distribution

176(84.2%) clinical trials were registered in ChiCTR and 33(15.8%) trials were registered in ClinicalTrials.gov. All the other ICMJE-accepted clinical trial registry contains no registration information of COVID-19. 33 of the 32 clinical trials registered on ClinicalTrials.gov are conducted in China.

Study type Among the 209 clinical studies, there were 152(72.7%) intervention trials, 46(22.0%) observational studies, 9(4.3%) diagnostic tests, and 2(1.0%) basic research. As for the specific study type, there were 5 single-arm trials,110(98 randomized controlled and 12 non-randomized controlled) 2-arm parallel-group trials, 37 (32 randomized controlled and 5 non-randomized controlled) multi-arm parallel-group trials, 7 cohort studies, 1 case-control study, the rest of the observational studies did not register a specific study type. Remarkably, 2 trials set “active comparator”, 4 trials uses “blank control”, 1 trial uses “historical comparison”, and 2 trials made a design of the real-world study (RWS).

It is worth noting that 8/9 of preventive trials and all the 7 convalescent trials are TCM-related trials, which indicates that TCM might play an important role in the prevention, control, and recovery of the epidemic. It reflects the advantages of TCM in the management of the epidemic.

Patients and objectives

According to the objectives and the eligibility criteria of the studies, the 152 intervention trials were divided into three categories: preventive trials, therapeutic trials, and convalescent trials. There were 9(4.3% in total)preventive trials, 136 (65.1% in total)therapeutic trials, and 7(3.3% in total)convalescent trials.

Interventions of studies

Among the 143 intervention trials on confirmed or suspected cases, the interventions mentioned mainly include 1. Antiviral drugs, such as Lopinavir /ritonavir tablets, Oseltamivir, Abidol, Remdesivir, Hydroxychloroquine, and so on; 2. Biological preparation, such as interferon a-1b, Human Immunoglobulin (pH4)for Intravenous Injection, convalescent plasma, mesenchymal stem cells(MSCs);3.Glucocorticoids, such as methylprednisolone;4. TCM injection, such as Xuebijing injection, Tanreqing injection, Xiyanping injection, Reducing injection; 5. Fixed TCM formulas or Chinese patent medicine, such as Lianhua Qingwen capsule/granule, Shuanghuanglian oral liquid, Jinye Baidu granule; 6. syndrome differentiation treatment of TCM: 7 Other intervention measures, such as Tai Chi, hydrogen-oxygen atomizer, vitamin C and so on (Figure 2).

Outcome Measures

There are great differences in primary outcomes of included studies And unreasonable outcome design is common. Among the 152 intervention studies,40 trials set more than 3 primary outcomes, of which 19trials set more than 3 primary outcomes without setting secondary outcomes.

Remarkable data of TCM

TCM-related studies were rapidly increased until February 2, on which the registration reached 20(76.9% at that time), while the registration of non-TCM-related studies was 6(23.1% at that time). Investigators of these TCM-related studies mostly come from institutions of Beijing or Guangzhou. It is worth noting that 8 of the 9 preventive trials and all the 7 convalescent trials, 2 real-world studies are TCM-related studies.

CISTANCHE

EFFECTS OF CISTANCHE: ANTI-INFLAMMATION

Discussion

By reading the included clinical research registration information and the data analysis above, we can draw the following conclusions: With the progress of the prevention and control of the epidemic, the number of registered clinical trials continues to grow. At this stage, clinical researches still take the treatment of COVID-19 as the main content, to explore an effective treatment, indicating that the epidemic management is still in a critical period, and the existing diagnosis and treatment guideline needs high-quality clinical evidence supporting. The number of preventive trials and convalescent trials indicates that TCM might have played an important role in the prevention, control, and recovery of the epidemic, which reflects the advantages of TCM in the management of the epidemic [3]. Elites in the field of TCM had shown a strong sense of scientific research at the early stage of the epidemic. Scholars from the China Academy of Chinese Medical Sciences, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Guangzhou University of TCM, and other institutions actively designed and organized clinical research, which played a leading role in TCM-related trials’ registration and conducting. Besides, the forms of TCM intervention measures are rich, having a low repetition rate of registered intervention measures. However, the overall number of TCM-related clinical trials is still less than that of non-TCM-related trials, which reflects the current situation that the volume of TCM is much smaller than that of western medicine.

The registration of quite a number of studies did not follow the principle of registration in the place of implementation, that is, it was conducted in China, but registered in the foreign clinical trials registry. Researchers should recognize that ICMJE has recognized not only ClinicalTrials.gov, UMIN-CTR, EudraCT, but also all the primary registries certified by WHO ICTRP since June 2007. Therefore, as a primary registry of WHO ICTRP, clinical trials registered in ChiCTR are also acknowledged by international journals. At the same time, it should also be reiterated that the opinion of “the purpose of registering clinical trials is to publish articles” is wrong. Clinical trial registration is the primary link of transparent reporting of clinical trials. It is an important part of medical research ethics, as well as the responsibility and obligation of researchers [4]. We found that a few researchers may have misunderstandings about some concepts of clinical trials. For example, there are obvious problems in filling in the items of “sponsor”, “Responsible Party” and “collaborator”; the inclusion criteria are too broad and the exclusion criteria were filled in “none”; inappropriate expressions such as “experimental group” are used in a grouping; the description of intervention measures is too vague, such as “treatment according to guidelines”, “TCM”, “antiviral treatment”; the setting of outcomes is unreasonable; “case-control study” or “cohort study” were filled in the study design, yet described the “intervention”.

The setting of blank control will bring ethical problems to the trial, especially in the intervention trials of diagnosed patients. Though there are few trials using blank control, the ethical approval department should pay attention to it. Despite the emergency of the epidemic, it is not appropriate to lower the ethical standards for approving research. Trials that have been approved by rapid ethical review should be continuously monitored [5].

The unreasonable outcome setting will bring problems to the interpretation of research results [6], make it difficult to compare similar research, and hinder the carrying out of high-quality secondary research. The irrational design of the primary outcome also suggests that there may be problems in the sample size setting of these studies [7]. The recent work of WHO and Chinese researchers to build a master protocol on clinical trials will contribute to the improvement of outcome measures in clinical trials’ design[8-10].

As mentioned above, many researchers are unclear about the concepts of clinical trials, and the methodological quality of clinical trials' design urges improving. Problems in the registration information of clinical trials involve all aspects of clinical trials, which not only hinders the transparent reporting of clinical trials but also the implementation of clinical trials, quality control, data collection and management, and reporting of trial results, causing waste of resources. Clinical front-line researchers should be aware of the importance of methodologists in the design of clinical trials.

In the study type of clinical trials, the “gold standard” randomized controlled trials (RCTs) still account for the largest proportion. Although the RCTs are in the highest evidence level of the original study, at the same time, the strict bias control level of RCTs brings high cost, high operation difficulty, and poor extrapolation [11]. RCTs may be more likely to be blocked in the current emergency of the epidemic.

In contrast, the single-arm test is an acceptable design in the absence of other reliable evidence [12]. Although a single-arm trial usually sets a non-strict control, the operation of the single-arm test is closer to the clinical practice and saves resources. Also, the application of real-world research concepts in trial design overcomes the flaw of the extrapolation of RCTs in some way [13]. If bias is properly controlled, well-designed observational studies can also provide us with valuable evidence [14]. Few of these types of studies were registered, researchers should be aware of this and design clinical trials according to the status of clinical practice in the epidemic.

CISTANCHE: IMPROVE IMMUNITY

EFFECTS OF CISTANCHE HERB: IMPROVE IMMUNITY

Conclusion

The clinical trial is the primary approach of clinical evidence production and an important part of clinical scientific research. At present, the demand for verifying clinical efficacy through clinical trials is increasing, but there are too many clinical trials were designed in low methodological quality. In the critical period of the epidemic, clinical trial design, including TCM, needs strict methodological control and fine management in order to produce reliable high-quality evidence and make due contributions for beating the epidemic.

References

1 National Health Commission of the people's Republic of China. [Internet].Announcement of National Health Commission of the people's Republic of China, No.1 of 2020. [cited 2020 February 19]. Available from: (Chinese)

2. ICMJE. [Internet]. Which trials registries are acceptable to the ICMJE?. [cited 2020 February 19].

3. National Health Commission of the people's Republic of China. [Internet].COVID-19's diagnosis and treatment Plan (trial Sixth Edition). [cited 2020 February 19]. (Chinese)

4. Wu TX, Minawaer A, Hao Y, et al. The past ten years of clinical trial registration in China: status and challenge.Chin J Evid-Based Med 2018, 18:522-525. (Chinese)

5. Zhang HH.[Internet]. Ethical Reflections for Conducting 2019-nCoV Related-Research During the Public Health Emergency. [cited 2020 February 19]. (Chinese)

6. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation, and elaboration: updated guidelines for reporting parallel group randomized trials.BMJ 2010, 340: c869.

7. Doctor Society of integrative Medicine, Chinese Medical Doctor Association (DSIM/CMDA), Professional committee on evidence-based medicine of Chinese association of integrative medicine, Guideline of clinical research methods of Integrated Traditional and Western Medicine. Chin J Integr Trad West Med 2015, 35:901-932. (Chinese)

8. Hu JY, Zhang XY, Zhao C, et al. Master protocol applied to the prevention and treatment of traditional Chinese medicine for coronary heart disease: ideas and methods of evidence-based optimization. Chin J Evid-Based Med 2019, 19:102-106. (Chinese)

9. World Health Organization. [Internet]. World experts and funders set priorities for COVID-19 research. [cited 2020 February 19].

10. Maxmen A. [Internet]. More than 80 clinical trials launch to test coronavirus treatments. [cited 2020 February 19].

11. Ahuja AS. Should RCTs be used as the gold standard for evidence-based medicine? Integrative Medicine Research 2019, 8:31-32.

12. Grayling MJ, Mander AP. Do single-arm trials have a role in drug development plans incorporating randomized trials? PHARM STAT 2016, 15:143-151.

13. Tian F, Xie YM. Real-world study: a potential new approach to effectiveness evaluation of traditional Chinese medicine interventions. J Chin Integr Med. 2010, 8:301-306. (Chinese)

14. Chen W, Fang SN, Liu JP, et al. Development and status of international evidence classification system of evidence-based medicine. Chin J Integr Trad West Med 2017, 37:1413-1419.

CISTANCHE SUPPLEMENT: IMPROVE IMMUNITY

EFFECTS OF CISTANCHE SUPPLEMENT: IMPROVE IMMUNITY

You Might Also Like